Tubulis Secures €128M Series B2 Funding for Cancer Treatment Advancements

Tubulis, a Munich-based biotech startup, has successfully closed an upsized €128 million Series B2 financing round to accelerate the clinical development of its solid tumor-focused ADC pipeline. The funding, co-led by EQT Life Sciences and Nextech Invest, with participation from global biotechnology investors, will support the evaluation of lead candidates TUB-030 and TUB-040, as well as technology development and expansion into the US market. Tubulis, a spin-off of LMU Munich and FMP Berlin, aims to revolutionize cancer therapy with novel ADCs tailored for specific indications. With over €187 million raised to date, Tubulis is poised to establish itself as a global leader in ADC therapeutics. The funding will also enable the company to expand its technology platforms and establish a US subsidiary, marking a significant milestone in its journey towards clinical-stage success.